ARS Pharmaceuticals (SPRY) Accumulated Depreciation & Amortization (2021 - 2024)
Historic Accumulated Depreciation & Amortization for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q4 2024 value amounting to $100000.0.
- ARS Pharmaceuticals' Accumulated Depreciation & Amortization changed 0.0% to $100000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $100000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $100000.0 for FY2024, which is 0.0% changed from last year.
- As of Q4 2024, ARS Pharmaceuticals' Accumulated Depreciation & Amortization stood at $100000.0, which was down 0.0% from $100000.0 recorded in Q3 2024.
- ARS Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $132000.0 for Q1 2024, and its period low was $14000.0 during Q4 2021.
- Moreover, its 4-year median value for Accumulated Depreciation & Amortization was $100000.0 (2022), whereas its average is $84700.0.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 61428.57% in 2022, then crashed by 4886.36% in 2024.
- Over the past 4 years, ARS Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $14000.0 in 2021, then surged by 614.29% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024.
- Its Accumulated Depreciation & Amortization stands at $100000.0 for Q4 2024, versus $100000.0 for Q3 2024 and $45000.0 for Q2 2024.